Addiction · NeuromodulationTrial Updateclinicalmid-term

Study on rTMS for Methamphetamine Abuse in Methadone Patients Launched

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 6:34:11 AM

Assessment confidence: 51% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial on rTMS for methamphetamine abuse in methadone patients could significantly influence treatment protocols in addiction therapies. Success in this trial may lead to new treatment options, impacting portfolio strategies for companies in the neuromodulation and addiction sectors. Regulatory context from FDA (FDA AP — METHADONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (3 high-relevance).

Strategic Assessment

If successful, this could open new avenues for treatment in addiction, impacting portfolio strategies for companies involved in neuromodulation and addiction therapies. The strongest clinical anchor is Transcranial Magnetic Stimulation for Methadone Maintenance Therapy Combined With Methamphetamine Abuse (ClinicalTrials.gov), patient population match (maintenance). In Addiction · Neuromodulation, 6 regulatory and 2 competitive items passed relevance filtering for addiction treatment protocols.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from SINGLE-AF Trial Evaluates DOACs in Intermediate Stroke Risk Atrial Fibrillation Patients.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — METHADONE HYDROCHLORIDE (SUPPL) (FDA). Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. Successful trial outcomes could lead to new treatment approvals and modifications in existing guidelines, affecting compliance and regulatory strategies for involved companies.

Key Risks

Elevated medium regulatory exposure for addiction treatment protocols could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the trial demonstrates efficacy, it could enhance market positioning for companies involved in addiction therapies, potentially increasing market share and revenue from new treatment options.
The London sandbox is a secure environment designed to safely test AI-enabled devices in a real-world environment so patients can benefit more quickly.
If successful, this could open new avenues for treatment in addiction, impacting portfolio strategies for companies involved in neuromodulation and addiction therapies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any subsequent publications regarding the efficacy and safety of rTMS in this context.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Pioneering AI health innovations regulatory sandbox launched
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Transcranial Magnetic Stimulation for Methadone Maintenance Therapy Combined With Methamphetamine Abuse
ClinicalTrials.govhigh relevance
Patient population match (maintenance)
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial of Treatments for COVID-19 in Hospitalized Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short Term Prognosis of Head and Neck Cancer Patients Receiving Curative Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
SINGLE-AF Trial Evaluates DOACs in Intermediate Stroke Risk Atrial Fibrillation Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment

Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

addiction treatment protocols

Commercial impact

medium

If the trial demonstrates efficacy, it could enhance market positioning for companies involved in addiction therapies, potentially increasing market share and revenue from new treatment options.

Regulatory impact

medium

Successful trial outcomes could lead to new treatment approvals and modifications in existing guidelines, affecting compliance and regulatory strategies for involved companies.

What to watch

Monitor trial results and any subsequent publications regarding the efficacy and safety of rTMS in this context.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.